Related Experiment Video
Updated: Apr 6, 2026

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
Rational design and synthesis of flavonolactam derivatives as potent topo I inhibitors with antitumor activity
Xiaoyu Shi1, Yaoguang Huang1, Xupeng Yang1
1School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, People's Republic of China.
Abstract:
Targeting topoisomerase I (Topo I) remains a pivotal strategy for the treatment of colorectal cancer (CRC). In this study, we rationally designed and synthesized a series of flavonolactam derivatives and systematically evaluated their biological activities and mechanisms of action. Among these, compounds NL-26 and NL-28 exhibited potent inhibitory effects on Topo I activity, arresting the cell cycle at the G2/M phase and inducing apoptosis to suppress tumor cell proliferation. Notably, NL-26 displayed the most potent Topo I inhibitory activity, which was comparable to that of the reference inhibitor camptothecin (CPT). In vivo pharmacokinetic studies revealed that NL-26 possesses a desirable profile, characterized by an AUC0-t of 1979.7 h ng/mL and a t1/2 of 3.7 h. Furthermore, NL-26 demonstrated robust antitumor efficacy in HCT116 xenograft models, achieving a tumor growth inhibition (TGI) of 55.1%. Collectively, these findings identify NL-26 as a promising lead compound and validate the flavonolactam scaffold as a privileged template for the development of next-generation Topo I-targeting therapeutics.
Insights
New flavonolactam derivatives show promise for colorectal cancer treatment. Compound NL-26 effectively inhibits topoisomerase I (Topo I), suppresses tumor growth in models, and warrants further investigation.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Topoisomerase I (Topo I) is a key target for colorectal cancer (CRC) therapy.
- Developing novel inhibitors with improved efficacy and pharmacokinetic profiles is crucial.
Purpose of the Study:
- To design, synthesize, and evaluate novel flavonolactam derivatives as Topo I inhibitors for CRC.
- To investigate the mechanism of action and in vivo efficacy of promising compounds.
Main Methods:
- Synthesis of a series of flavonolactam derivatives.
- In vitro evaluation of Topo I inhibitory activity and cell cycle arrest.
- Apoptosis induction assays.
- In vivo pharmacokinetic and antitumor efficacy studies in HCT116 xenograft models.
Main Results:
- Compounds NL-26 and NL-28 demonstrated potent Topo I inhibition.
- NL-26 exhibited strong Topo I inhibitory activity, comparable to camptothecin (CPT).
- NL-26 showed favorable pharmacokinetics (AUC 1979.7 µgh/mL, t1/2 3.7 h) and significant antitumor efficacy (55.1% TGI) in vivo.
Conclusions:
- NL-26 is identified as a promising lead compound for CRC therapy.
- The flavonolactam scaffold is validated as a valuable template for developing novel Topo I inhibitors.
More Related Videos
10:13Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
10:17Efficient Construction of Drug-like Bispirocyclic Scaffolds Via Organocatalytic Cycloadditions of α-Imino γ-Lactones and Alkylidene Pyrazolones
Published on: February 7, 2019
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis